Review
Extended-release trazodone (Oleptro) for depression
- PMID: 21068704
Item in Clipboard
Review
Extended-release trazodone (Oleptro) for depression
Med Lett Drugs Ther.
.
Abstract
The FDA has approved the marketing of an extended-release formulation of trazodone (Oleptro--Angelini Labopharm) for treatment of major depressive disorder in adults. Immediate-release trazodone has been available for treatment of depression for many years, but is used mostly in low doses for its sedating effects.
Similar articles
-
Rediscovering trazodone for the treatment of major depressive disorder.CNS Drugs. 2012 Dec;26(12):1033-49. doi: 10.1007/s40263-012-0010-5. CNS Drugs. 2012. PMID: 23192413 Free PMC article. Review.
-
A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.Curr Med Res Opin. 2006 Sep;22(9):1703-13. doi: 10.1185/030079906X121039. Curr Med Res Opin. 2006. PMID: 16968574 Clinical Trial.
-
Dose proportionality of once-daily trazodone extended-release caplets under fasting conditions.J Clin Pharmacol. 2010 Dec;50(12):1438-49. doi: 10.1177/0091270009360979. Epub 2010 Feb 19. J Clin Pharmacol. 2010. PMID: 20173086 Clinical Trial.
-
Efficacy and safety of prolonged-release trazodone in major depressive disorder: a multicenter, randomized, double-blind, flexible-dose trial.Pharmacology. 2014;94(5-6):199-206. doi: 10.1159/000368559. Epub 2014 Nov 5. Pharmacology. 2014. PMID: 25376160 Clinical Trial.
-
Bupropion extended-release for depressive disorders.Expert Rev Neurother. 2008 May;8(5):715-22. doi: 10.1586/14737175.8.5.715. Expert Rev Neurother. 2008. PMID: 18457528 Review.
Cited by
-
Rediscovering trazodone for the treatment of major depressive disorder.CNS Drugs. 2012 Dec;26(12):1033-49. doi: 10.1007/s40263-012-0010-5. CNS Drugs. 2012. PMID: 23192413 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
